scispace - formally typeset
C

Chris J.L.M. Meijer

Researcher at VU University Amsterdam

Publications -  745
Citations -  83366

Chris J.L.M. Meijer is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Cervical cancer & Cervical intraepithelial neoplasia. The author has an hindex of 128, co-authored 733 publications receiving 78705 citations. Previous affiliations of Chris J.L.M. Meijer include VU University Medical Center & Academic Center for Dentistry Amsterdam.

Papers
More filters
Journal ArticleDOI

Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape

TL;DR: Multiplex qMSP offers a promising approach for high-throughput diagnostic analysis of the methylation status of multiple genes, which after proper design and validation can be equally specific, sensitive and reproducible as its singleplex versions.
Journal ArticleDOI

Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome

TL;DR: It is hypothesized that DR+/CLIP− AML blasts are able to present leukemia-specific antigens to CD4+ T helper cells initiating an effective and long-lasting antitumor response resulting in a prolonged disease-free survival.
Journal ArticleDOI

Clusterin: a protective mediator for ischemic cardiomyocytes?

TL;DR: It is concluded that ischemia induces the upregulation of clusterin in ischemically challenged, but viable, cardiomyocytes and suggests that clusterin protects cardiomers against ischemic cell death via a complement-independent pathway.
Journal ArticleDOI

Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area

TL;DR: The screening programme in The Netherlands as executed in the Greater Amsterdam area is associated with a decreased incidence and increased survival of patients with squamous cell carcinoma, but fails to detect (pre)malignant lesions of adenocarcinoma.
Journal ArticleDOI

Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa.

TL;DR: The data suggest that current prophylactic HPV vaccines against HPV16 and 18 may prevent similar proportions of cervical SCC in HIV‐positive as in HIV-negative women provided that vaccine‐related protection is sustained after HIV infection.